Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-Naïve patients prescribed efavirenz compared to atazanavir/ritonavir

Daria Gotti, Bruno Mario Cesana, Laura Albini, Alessandra Calabresi, Ilaria Izzo, Emanuele Focà, Davide Motta, Rita Bellagamba, Rita Fezza, Pasquale Narciso, Laura Sidhinolfi, Paolo Maggi, Nigritella Brianese, Eugenia Quiros-Roldan, Giovanni Guaraldi, Carol Torti

Research output: Contribution to journalArticle

Abstract

Background: Cardiovascular risk in HIV-infected patients is related, at least in part, to serum lipid alterations before and after HAART. Lipoprotein-particle subclasses may also have an effect, but comparative data after standard HAART regimens are limited.Methods: This was a substudy of a trial in 91 antiretroviral-naïve patients randomized to tenofovir + emtricitabine + atazanavir/ritonavir (ATV/r) or efavirenz (EFV). Over-time trends from baseline to week 48 in total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), HDL particles (HDLp), and TC:HDL-C and TG:HDL-C ratios were analyzed by analysis of covariance (ANCOVA). Furthermore, confidence intervals for differences between the 2 groups at week 48 were calculated. Indications for lipid-lowering interventions and low HDL-C were also studied.Results: ANCOVA showed that, with respect to patients receiving ATV/r, those prescribed efavirenz (EFV) had greater increases reported as mean differences in lipid values at week 48: 14 mg/dL (95% CI, 0.2 to 27) for TC, 14 mg/dL (95% CI, 4 to 25) for LDL-C, 5 mg/dL (95% CI, 2 to 9) for HDL-C, and 2.2 mg/dL (95% CI, 0.4 to 4) for large HDLp. Proportions of subjects with indications for lipid-lowering interventions and with HDL-C

Original languageEnglish
Pages (from-to)245-255
Number of pages11
JournalHIV Clinical Trials
Volume13
Issue number5
DOIs
Publication statusPublished - Jan 1 2012

Keywords

  • antiretroviral therapy
  • cardiovascular risk
  • human immunodeficiency virus
  • lipids
  • lipoproteins

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-Naïve patients prescribed efavirenz compared to atazanavir/ritonavir'. Together they form a unique fingerprint.

  • Cite this

    Gotti, D., Cesana, B. M., Albini, L., Calabresi, A., Izzo, I., Focà, E., Motta, D., Bellagamba, R., Fezza, R., Narciso, P., Sidhinolfi, L., Maggi, P., Brianese, N., Quiros-Roldan, E., Guaraldi, G., & Torti, C. (2012). Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-Naïve patients prescribed efavirenz compared to atazanavir/ritonavir. HIV Clinical Trials, 13(5), 245-255. https://doi.org/10.1310/hct1305-245